Last updated: 2026-09-05 21:03:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Design Therapeutics, Inc. (DSGN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $15.14, with a market capitalization of $971.89M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5.28 to $17.25. This page covers its latest market performance, valuation, price trends and company information.
$971.89M | |
$14.96 | |
$50.50 | |
$1.94 | |
$15.03 | |
206.28K | |
-- | |
-- | |
$17.25 | |
$5.28 | |
-- | |
-- |
Design Therapeutics, Inc. (DSGN) last closed at $15.03 as of 2026-09-04 23:31:00, unchanged from the previous close of $15.03.
During the latest regular trading session, DSGN traded between $1.94 and $50.50, with a volume of 206.28K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Design Therapeutics, Inc. (DSGN) moved from $15.00 to $15.14, representing a gain of 0.90% ($0.13).
The stock traded between $14.40 and $15.33 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 575.35 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 82.3%
DSGN is currently trading at $15.14, placing it 82.3% of the way from its 52-week low of $5.28 to its 52-week high of $17.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 55 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Design Therapeutics, Inc. (DSGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.